Group 1 - The core point of the news is that 创胜集团-B (06628) announced a share placement of 14.4 million shares at a price of HKD 4.33 per share, representing an approximate discount of 18.76% compared to the closing price of HKD 5.33 on September 9 [1] - The net proceeds from the placement are expected to be approximately HKD 59.34 million, with 40% allocated for clinical development of pipeline assets TST001 and TST002, 30% for advancing promising preclinical pipeline assets TST801, TST013, and TST786, and 30% for working capital and general purposes [1] Group 2 - 华兴证券 reported that 创胜集团 has made significant breakthroughs in research and clinical development, with TST001 showing a median overall survival (mOS) of 20.4 months in a study involving 82 patients with gastric cancer [2] - Following regulatory approval, TST001 is set to initiate a global Phase III clinical trial targeting gastric cancer/gastroesophageal cancer [2] - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China with positive early results, and the company has also made early clinical progress with innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]
港股异动 | 创胜集团-B(06628)早盘跌超9% 公司拟折价超18%配股筹资 用于TST001等药物研发